Venrock Healthcare Capital Partners III, L.P., 10% Owner at KalVista Pharmaceuticals, Inc. (KALV), bought 176,198 shares at $14.47 ($2.5M) on 2024-01-30, disclosed to the SEC on 2024-02-01.
Open-market purchase of $2.5M KALV by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.47 | 88,099 | $1.3M | 50.0% |
| 2 | $14.47 | 88,099 | $1.3M | 50.0% |
| Total | $14.47 avg | 176,198 | $2.5M | 100% |
| Filing → |
| KALV | BUY | 2024-01-29 | $1.4M | — | Filing → |
| KALV | BUY | 2024-01-10 | $2.8M | — | Filing → |
| UMRX | BUY | 2020-08-18 | $1.4M | — | Filing → |